Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Aditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
Tag facets appear after tag usage counts are rebuilt.
Adaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenCitigroup is a globally important bank with FY2025 revenue of $85.2 billion, Q1 2026 revenue of $24.6 billion and $1.45 trillion of deposits, but the thesis depends on deposit stability, credit, capital and simplification execution.
OpenBank of America reported FY2025 revenue of $113.1 billion, FY2025 net income of $30.5 billion and Q1 2026 net income of $8.6 billion. The thesis is deposit durability, capital discipline and credit quality through the rate cycle.
Open20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAgenus has pushed BOT plus BAL into a global Phase 3 colorectal cancer trial and is generating early access revenue, but the current thesis is a race between regulatory progress and financing pressure: Q1 cash was $35.0M, operating cash flow was negative, the
OpenAssured Guaranty is a financial guaranty insurer with Q1 2026 new-business growth, record adjusted book value per share and a long buyback record, but the equity case still depends on ratings strength, insured-credit losses, PREPA and disciplined capital alloc
OpenAGNC is a leveraged Agency MBS mortgage REIT. Q1 2026 spread income covered the common dividend, but tangible book value fell and the common equity remains tied to mortgage spreads, repo funding, hedge performance and leverage.
OpenAgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
OpenFarmer Mac is compounding a record rural-credit book with strong spread income and capital headroom, but AGM holders own non-voting common in a highly levered GSE whose thesis depends on funding access, agricultural credit quality, policy treatment and discipl
OpenAGM.A is Farmer Mac's Class A voting common stock, with real board-election rights for eligible non-Farm Credit System financial institutions and the same declared common dividend as AGM, but ownership restrictions, narrow holder eligibility, related-party con
OpenAEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
OpenAegon is trying to simplify into a U.S.-centered Transamerica story by 2028, with FY2025 capital generation, WFG growth, legacy-risk cleanup, and a GBP 2.0 billion UK sale all pointing in the same direction.
OpenAddex has real allosteric-modulator science, but the public-company story now turns on CHF 1.6 million of year-end cash, a delayed 2025 Form 20-F, chronic-cough preclinical data, dipraglurant repositioning, and a 20% Neurosterix option.
OpenAdvanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
OpenADIL has a genetically targeted alcohol-use-disorder drug candidate, a proposed European partner, and a possible simpler Phase 3 path, but the company has no product revenue and cash only into the second half of 2026.
OpenADCT already sells ZYNLONTA, but the story is not solved by having revenue. The next question is whether the 2026 lymphoma data can widen the drug's role before cash burn, royalties, debt, and dilution take the lead.
OpenEnact is profitable, overcapitalized against PMIERs, and returning cash through dividends and buybacks, but the public-company thesis still runs through mortgage credit, GSE rules, housing affordability, reinsurance markets, and Genworth's 81% control.
OpenOfficial-source baseline for Abeona Therapeutics using SEC submissions, SEC company facts, the FY2025 10-K, latest available 10-Q, filed FY2025 results release, filed launch update, 2026 proxy materials, and FDA product approval sources.
OpenOfficial-source baseline for Ameris Bancorp using SEC submissions, SEC company facts, the FY2025 10-K, Q1 FY2026 10-Q, Q1 2026 filed earnings release and presentation, proxy materials, and FDIC industry context.
OpenSigned-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Tag facets appear after tag usage counts are rebuilt.